This review is a summary of an individual study; Adjuvant dabrafenib plus trametinib in stage III BRAF V600-mutated melanoma: longer follow-up confirms relapse-free survival benefit. This study involved 169 sites across 25 countries.
Independent commentary is provided by Dr. Rachel Roberts-Thomson, a Medical Oncologist at The Queen Elizabeth Hospital and with Adelaide Oncology and Haematology.
Please login below to download this issue (PDF)